Navigation Links
Clinical trial will test new HIV/AIDS vaccine
Date:4/3/2008

BOSTON A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Womens Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

This study will involve 48 healthy volunteers who will receive either two or three immunizations and who will be followed to assess the safety and immunogenicity of the vaccine, explains Lindsey R. Baden, MD, Assistant Professor of Medicine at BWH and Harvard Medical School and Protocol Chair for the study.

The vaccine consists of a replication-incompetent, recombinant adenovirus serotype 26 (rAd26) vector encoding an HIV-1 envelope gene.

The rAd26 vaccine vector was selected for its particularly low seroprevalence in human populations and for its potent immunogenicity and protective efficacy in preclinical studies, explains Dan H. Barouch, MD, PhD, Associate Professor of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School and Principal Investigator of the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program that developed the vaccine. This program is sponsored by the Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Manufactured by the Dutch biotechnology company Crucell Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from academia and industry in an effort to accelerate the development of promising HIV/AIDS vaccine candidates. The novel strategy used in developing this vaccine enables researchers to circumvent preexisting immunity to the adenovirus serotype 5, the virus responsible for the common cold, which has recently shown limitations as an HIV-1 vaccine vector.

The rAd26 vector does not regularly occur in the human population and huma
'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... How well patients recover from cancer surgery may ... and the operations themselves. Family conflicts and other ... complications, a Mayo Clinic study has found. Addressing ... patients, stress, speed their recoveries and save health ... looked at colon cancer patients, and found that ...
(Date:9/2/2014)... suggests that the key to more youthful immune function ... report published in the Journal of Leukocyte ... lungs of old mice had different responses to ... these changes were reversed by ibuprofen. , "Inflammation in ... said Joanne Turner, Ph.D., a researcher involved in the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... Will Continue to be Used in Early ... from Decision Resources, WALTHAM, Mass., Oct. ... leading research and advisory firms focusing on ... is currently the leading biologic for Crohn,s ...
... 1, 2008 at this year,s liver ... SAN FRANCISCO, Oct. 27 Researchers analyzed 43,497,patients ... 22,863 adults,who received transplantation to determine the best time ... caused by differences in donor type was vastly offset ...
... 27 ReachMD XM 157 announces a new,"Medical ... receptor,antagonist and its effects on management of euvolemic ... XM 157, the first and only network for ... the Tide Against,Hyponatremia" four times a day October ...
... NORWALK, Conn., Oct. 27 Maclaren USA Inc.,announces the ... Chief Operation Officer., "Maclaren,s growth has been extraordinary ... our new from-birth transport system, the Grand Tour(TM),LX, is ... proven themselves to be exceptional leaders in their field. ...
... has donated a portable Automatic External Defibrillator (AED) to Habitat ... ... Newtown, Pennsylvania (PRWEB) October 27, 2008 -- HeartSine Technologies, ... donated a portable Automatic External Defibrillator (AED) to Habitat for ...
... reduced inflammation, cholesterol and belly fat , , SUNDAY, Oct. ... diet." , New research ties eating tart cherries ... weight and fat -- all major risk factors for ... presented by University of Michigan researchers at the American ...
Cached Medicine News:Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 3Health News:Maclaren Appoints New President and New Chief Operation Officer 2Health News:HeartSine Portable Defibrillator Donation Brings Added Safety to Habitat for Humanity of Charlotte ReStore Location 2Health News:Cherry-Enriched Diet Cut Heart Risks in Rats 2
(Date:9/2/2014)...  Volcano Corporation (Nasdaq: VOLC ), ... economic outcomes on a global basis by developing ... visualization, physiology diagnostics and therapies, said today that ... Healthcare conference on Tuesday, September 9. ... and chief executive officer, will begin at 11:10 ...
(Date:9/2/2014)... , Sept. 2, 2014  VentiRx Pharmaceuticals, ... to the development and commercialization of novel ... an update on corporate and clinical activities ... for future funding, ongoing clinical trials and ... In corporate news, Chief Executive Officer Robert ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced that the U.S. Food and ... designation to the investigation of motolimod (VTX-2337) ... doxorubicin (PLD) for the treatment of women ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... 5, 2011 Reportlinker.com announces that ... available in its catalogue: ... Cosmetic Surgery, Facial Aesthetic and Medical ... http://www.reportlinker.com/p0610527/Emerging-Markets-Chinese-and-Indian-Cosmetic-Surgery-Facial-Aesthetic-and-Medical-Laser-Markets-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply The ...
... 2011 The Board of Directors of MSA (NYSE: ... a Vice President of the company, responsible for Global Product ... of November 1, will assume the role of President of ... (MEZ).  In his new role, Dr. Muschter will become a ...
Cached Medicine Technology:Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 2Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 3Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 4Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 5Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 6Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 7Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 8Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 9Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 10Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 11Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 12Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 13Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 14Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 15Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 16Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 17Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 18MSA Elects Dr. Thomas Muschter to Vice President 2
... KIMBERLY-CLARK BALLARD Adult TRACH ... in T-Piece, Elbow and Double ... separate from vials; 12 vials ... Offers multiple tracheostomy sizes, French ...
... KIMBERLY-CLARK BALLARD Adult TRACH ... designed and labeled for ... Features an isolated cleaning ... minimize potential for contamination ...
... Maxi-Flo® suction catheters ... or straight. , ... catheter kits are latex-free., ... feature a catheter tip ...
... are available with a single lumen or ... swivel, MDI adapter., ,Trac-Wedge™ device, and ... include a patient label. Dual swivel elbow ... All Portex® Steri-Cath® systems are latex-free. , ...
Medicine Products: